SCHEMBL2169990

SCHEMBL2169990

O=C1CN(S(=O)(=O)Cc2ccccc2)N1C1C2CC3CC(C2)CC1C3

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.45
CTSG P08311 1/20 0.43
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
KMT2A Q03164 2/20 0.39
POLB P06746 2/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PARP1 P09874 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172137 0.80 MMP2 (0.45) HSD11B1CTSGTSHRKMT2APOLB
SCHEMBL2170837 0.75 HSD11B1 (0.46) HSD11B1CTSGHPGDTSHRALDH1A1
SCHEMBL2168896 0.69 MMP2 (0.48) CTSGTSHRKMT2APOLBALDH1A1
SCHEMBL2169858 0.69 MMP2 (0.48) HSD11B1CTSGTSHRKMT2APOLB
SCHEMBL19798474 0.69 CHRM2 (0.50) HSD11B1CTSGHPGDTSHRKMT2A
SCHEMBL2170178 0.69 SMN1; SMN2 (0.44) HSD11B1CTSGKMT2AALDH1A1NPSR1
SCHEMBL2169144 0.68 HSD11B1 (0.47) HSD11B1TSHRKMT2AALDH1A1MEN1
SCHEMBL2174029 0.67 MMP2 (0.51) HSD11B1CTSGTSHRALDH1A1MAPT
SCHEMBL19798440 0.65 CRBN (0.44) HSD11B1HPGDTSHRRAB9A
SCHEMBL2169240 0.65 HSD11B1 (0.44) HSD11B1TSHRKMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885CTSG 3929/4885HPGD 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.